UK-based CHARM Therapeutics Ltd has raised $80 million from an international investor syndicate to support a preclinical product, based on a novel algorithm, for patients with acute myeloid leukaemia (AML). AML accounts for about one out of three leukaemias in adults in the US, but for those over the age of 65 years, the incidence is much higher. Announced on 2 September, the financing was co-led by new investors New Enterprise Associates and SR One with participation from existing groups including NVentures, the investment arm of the chipmaker Nvidia Corp.
